Dr. Sharman explains the impact of using NMR for the quality control and release of drug molecules currently in shortage due to the Coronavirus pandemic.

We are living through a public health crisis the likes of which has not been seen for generations. But we go into this crisis with one key advantage compared to previous generations – our scientific knowledge and capabilities are a major weapon against the virus, and we find ourselves in a race against time to develop effective therapies and preventative treatments. NMR is a key technique that forms a part of the backbone of analytical chemistry which so underpins much of drug discovery, development and manufacturing.

During this webinar hosted by Bruker, Dr. Gary Sharman stresses the importance of NMR in this process, with particular reference to COVID-19. He focuses primarily on the impact of using NMR for the quality control and release of existing drug molecules which are in shortage for one reason or another due to the pandemic, and on the solutions which can assist in this process. This presentation will be of particular interest to both spectroscopists and non-NMR experts alike.


Senior Scientific Director

Gary recently joined Mestrelab after more than 20 years working in the Pharma industry, most recently for Eli Lilly where he spent 15 years in discovery chemistry at the Erl Wood site in the UK, He worked within the analytical chemistry group, specializing in NMR spectroscopy and the processing and management of data. Prior to that he worked in the NMR group at AstraZeneca, within the development chemistry group at Macclesfield UK. Gary studied for a PhD entitled “structure elucidation and molecular recognition in Secondary metabolites” with Professor Dudley Williams at the University of Cambridge, where he also completed his undergraduate degree in Natural Sciences.

Production Partner

Bruker Corporation

Bruker offers preclinical imaging solutions for a broad spectrum of application fields, such as cancer research, neuroimaging and cardiac disease.

Additional Content From Bruker Corporation

Related Content